Skip to main content
Advertisement

Main menu

  • Home
  • Content
    • Current Issue
    • Publication Preview--Ahead of Print
    • Past Issue Archive
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
    • COVID-19 Content and Resources
  • For Authors
  • About Us
    • About AJNR
    • Editors
    • American Society of Neuroradiology
  • Submit a Manuscript
  • Podcasts
    • Subscribe on iTunes
    • Subscribe on Stitcher
  • More
    • Subscribers
    • Permissions
    • Advertisers
    • Alerts
    • Feedback
  • Other Publications
    • ajnr

User menu

  • Subscribe
  • Alerts
  • Log in

Search

  • Advanced search
American Journal of Neuroradiology
American Journal of Neuroradiology

American Journal of Neuroradiology

  • Subscribe
  • Alerts
  • Log in

Advanced Search

  • Home
  • Content
    • Current Issue
    • Publication Preview--Ahead of Print
    • Past Issue Archive
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
    • COVID-19 Content and Resources
  • For Authors
  • About Us
    • About AJNR
    • Editors
    • American Society of Neuroradiology
  • Submit a Manuscript
  • Podcasts
    • Subscribe on iTunes
    • Subscribe on Stitcher
  • More
    • Subscribers
    • Permissions
    • Advertisers
    • Alerts
    • Feedback
  • Follow AJNR on Twitter
  • Visit AJNR on Facebook
  • Follow AJNR on Instagram
  • Join AJNR on LinkedIn
  • RSS Feeds
LetterLetter

Consider Using Diffusion Tensor Imaging in Geron Phase I Trial

C.B. Patel
American Journal of Neuroradiology August 2009, 30 (7) e97; DOI: https://doi.org/10.3174/ajnr.A1632
C.B. Patel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • References
  • PDF
Loading

The first-time approval of human embryonic stem cell (hESC)-based therapy by the US Food and Drug Administration has highlighted the application of regenerative medicine to human spinal cord injury (SCI). As a result, attention has recently focused on the potential promises and perils of Geron Corporation’s (Menlo Park, Calif) hESC-derived oligodendrocyte progenitor cells (OPCs) in the treatment of human SCI.1 The rationale for the OPC therapy is that remyelination (by oligodendrocytes) of damaged spinal cord axons may improve nerve conduction and, thereby, perhaps neuromotor recovery in patients with SCI. Although the end points for the Geron phase I multicenter SCI trial are primarily safety and secondarily efficacy,2 the addition of noninvasive diffusion tensor imaging (DTI) to track patients treated with OPCs would enhance assessment of the therapy.

DTI, a newer MR imaging technique, provides quantitative information about axonal structure. Of relevance to the recently approved Geron study, on the basis of rodent models of SCI, the DTI measure of transverse diffusivity has been shown to be correlated with demyelination,3 whereas the DTI measure of longitudinal diffusivity has been shown to be correlated with axonal damage.4 In animal models, research is underway to elucidate the sensitivity and specificity of DTI measures for the various pathologies caused by SCI. Given the correlations that exist between conventional MR imaging measures and the degree of myelination,5 longitudinally tracking DTI measures from baseline scan values could provide investigators with additional information about changes in the state of axonal integrity and myelination after OPC therapy.

In addition to the presence of skilled neurosurgical and neuroradiologic teams for the intraspinal injection of OPCs, the presence of human DTI scanning capability should be considered when selecting clinical sites for enrollment of study participants. Indeed, the use of MR imaging to monitor cell transplant therapies in human SCI is not new; Féron et al6 used conventional MR imaging to scan spinal cords 1 year posttransplantation of autologous olfactory ensheathing cells in patients with SCI. However, using DTI in conjunction with conventional MR imaging techniques to image and monitor the progress of this novel therapy would increase the assessment potential of its phase I trial.

References

  1. ↵
    Couzin J. Biotechnology: celebration and concern over U.S. trial of embryonic stem cells. Science 2009;323:568
    Abstract/FREE Full Text
  2. ↵
    Geron Corporation. Geron receives FDA clearance to begin world’s first human clinical trial of embryonic stem cell-based therapy. Available at: http://geron.com/grnopc1clearance/grnopc1-backgrounder.pdf. Accessed February 5,2009
  3. ↵
    Herrera JJ, Chacko T, Narayana PA. Histological correlation of diffusion tensor imaging metrics in experimental spinal cord injury. J Neurosci Res 2008;86:443–47
    CrossRefPubMed
  4. ↵
    Budde MT, Kim JH, Liang HF, et al. Toward accurate diagnosis of white matter pathology using diffusion tensor imaging. Magn Res Med 2007;57:688–95
    CrossRefPubMed
  5. ↵
    Mori S, Zhang J. Principles of diffusion tensor imaging and its applications to basic neuroscience research. Neuron 2006;51:527–39
    CrossRefPubMed
  6. ↵
    Féron F, Perry C, Cochrane J, et al. Autologous olfactory ensheathing cell transplantation in human spinal cord injury. Brain 2005;128:2951–60
    Abstract/FREE Full Text
  • American Society of Neuroradiology
PreviousNext
Back to top

In this issue

American Journal of Neuroradiology: 30 (7)
American Journal of Neuroradiology
Vol. 30, Issue 7
August 2009
  • Table of Contents
  • Index by author
Advertisement
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on American Journal of Neuroradiology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Consider Using Diffusion Tensor Imaging in Geron Phase I Trial
(Your Name) has sent you a message from American Journal of Neuroradiology
(Your Name) thought you would like to see the American Journal of Neuroradiology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Consider Using Diffusion Tensor Imaging in Geron Phase I Trial
C.B. Patel
American Journal of Neuroradiology Aug 2009, 30 (7) e97; DOI: 10.3174/ajnr.A1632

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Consider Using Diffusion Tensor Imaging in Geron Phase I Trial
C.B. Patel
American Journal of Neuroradiology Aug 2009, 30 (7) e97; DOI: 10.3174/ajnr.A1632
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Purchase

Jump to section

  • Article
    • References
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Crossref
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

More in this TOC Section

  • Fair Performance of CT in Diagnosing Unilateral Vocal Fold Paralysis
  • Reply:
  • Regarding “Altered Blood Flow in the Ophthalmic and Internal Carotid Arteries in Patients with Age-Related Macular Degeneration Measured Using Noncontrast MR Angiography at 7T”
Show more LETTERS

Similar Articles

Advertisement

News and Updates

  • Lucien Levy Best Research Article Award
  • Thanks to our 2022 Distinguished Reviewers
  • Press Releases

Resources

  • Evidence-Based Medicine Level Guide
  • How to Participate in a Tweet Chat
  • AJNR Podcast Archive
  • Ideas for Publicizing Your Research
  • Librarian Resources
  • Terms and Conditions

Opportunities

  • Share Your Art in Perspectives
  • Get Peer Review Credit from Publons
  • Moderate a Tweet Chat

American Society of Neuroradiology

  • Neurographics
  • ASNR Annual Meeting
  • Fellowship Portal
  • Position Statements

© 2023 by the American Society of Neuroradiology | Print ISSN: 0195-6108 Online ISSN: 1936-959X

Powered by HighWire